Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Direct oral Anticoagulants for Prevention of Left Ventricular Thrombus after Anterior Acute Myocardial Infarction (Rivaroxaban 2.5 mg + DAPT vs DAPT)
2021-001534-19Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in Left ventricular thrombosis (LVT) and myocardial infarction (MI) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Left ventricular thrombus at 1 month by DE-CMR. Started Mar 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Left ventricular thrombosis (LVT)myocardial infarction (MI)
Beyond the preview
Go deeper on 2021-001534-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001534-19.